MedX Health Announces Regulatory Approval in Australia

MISSISSAUGA, ONTARIO--(Marketwired - Sept. 25, 2014) - MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE:MDX) announced that it has received certification by the Australian Register of Therapeutic Goods ("ARTG") for its SIAscopy skin screening technology in Australia.

"This important approval allows us to sell our SIAscopy products into Australia, where unfortunately there are two to three times the skin cancer rates compared with North America" commented Rob von der Porten, President and CEO. "The awareness of skin cancer and the need for regular assessments of moles, lesions and other suspicious skin abnormalities is very high in Australia, to the point where it is considered routine within medical practices. Expanding our sales into Australia will augment our progress in Europe, which began earlier this year after gaining the CE Mark."

MedX has established an exclusive distribution arrangement with one of the largest medical device distributors in Australia to market SIAscopy. The Company will begin shipping units to its distribution partner in the fourth quarter.

According to Cancer Council Australia, physicians perform more than one million patient consultations for skin cancer annually. MedX's SIAscopy skin analysis technology is fast, non-invasive and painless, ideally suited to provide a physician with a tool to assist in making a correct assessment of a patient's skin condition in real time.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer screening; it manufactures and distributes its SIAscopy™ product line, including SIMSYS™ and MoleMate™, hand-held devices that use patented technology utilizing light and its remittance to view beneath suspicious moles and lesions in a pain free, non-invasive manner, creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians, clinics as well as being deployed in Norway in drugstore settings where the images are sent remotely to dermatologists who perform a diagnosis. These products are FDA (US) cleared, Health Canada, CE and now ARTG approved for use in the US, Canada, Europe and Australia. MedX also designs, manufactures and distributes quality low level laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, providing drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit www.medxhealth.com.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.